ArticleThe Lancet regional health. Western Pacific2021
The changing landscape of anti-lung cancer drug clinical trials in mainland China from 2005 to 2020.
Article in The Lancet regional health. Western Pacific, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- The clinical trial landscape of bispecific antibodies in non-small cell lung cancer: mechanistic trends and developmental strategies.Frontiers in pharmacology · 2026Pooled it
- Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020.JAMA network open · 2022Pooled it
- Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non-small cell lung cancer: A systematic review and meta-analysis.Investigational new drugs · 2022Pooled it
- Trial
- Landscape of diabetic kidney disease drug clinical trials in China (2013-2023): global implications for innovation and policy.Renal failure · 2026Review
- Epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of non-small cell lung cancer in the past 30 years (1997-2026).Chinese medical journal · 2026Review
- A functional view on the enhanced therapeutic effects of the control-released recombinant human endostatin.American journal of nuclear medicine and molecular imaging · 2026Article
- Unexpected metastasis of thyroid cartilage involvement from lung adenocarcinoma: A case report.World journal of clinical cases · 2025Article
- The Changing Landscape of Heart Failure Drug Clinical Trials in China, 2013-2023.Drug design, development and therapy · 2025Review
- Predicting epidermal growth factor receptor mutations in non-small cell lung cancer through dual-layer spectral CT: a prospective study.Insights into imaging · 2024Article
- From past to present: tracing the trends of diabetes drug trials in mainland China.Frontiers in endocrinology · 2024Article
- Recombinant human endostatin as a potential anti-angiogenic agent: therapeutic perspective and current status.Medical oncology (Northwood, London, England) · 2023Review
- Article
- Proteins from Blackberry Seeds: Extraction, Osborne Isolate, Characteristics, Functional Properties, and Bioactivities.International journal of molecular sciences · 2023Article
- Informed consent in cancer clinical drug trials in China: a narrative literature review of the past 20 years.Trials · 2023Review
- The changing landscape of drug clinical trials on cardiometabolic diseases in China, 2009-2021.Diabetology & metabolic syndrome · 2023Article
- Landscape of the clinical development of China innovative anti-lung cancer drugs.Cancer pathogenesis and therapy · 2023Review
- Changes in Drug Clinical Trials of Thyroid Diseases in China, 2009-2022.Drug design, development and therapy · 2023Article
- The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non-small cell lung cancer: A real-world study.Thoracic cancer · 2022Article
- Evolution of ischemic stroke drug clinical trials in mainland China from 2005 to 2021.CNS neuroscience & therapeutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn recent years, new drug development on lung cancer is in full swing in China. The aim of this study was to overview the changing landscape of anti-lung cancer drug clinical trials in mainland China from 2005 to 2020.
methodsWe analysed anti-lung cancer drug clinical trials registered on three websites including the China National Medical Products Administration Centre for Drug Evaluation platform, the Chinese Clinical Trial Registry and ClinicalTrials.gov.
findingsA total of 1595 anti-lung cancer drug clinical trials from Jan 1st, 2005 to Dec 31st, 2020 were extracted, which included 630 (39•5%) investigator-initiated trials (IITs), 698 (43•8%) domestic industry-sponsored trials (ISTs), and 267 (16•7%) international ISTs. During the past 16 years, the number of anti-lung cancer clinical trials including IITs and domestic ISTs had a remarkable growth, however, the number of international ISTs increased slowly. The number of principal clinical trial units also increased significantly over time. Of the 1595 trials, the largest growth was observed in phase I trials during 2013-2020, with an average annual growth rate of 38•6%. 278 trials were led by principal investigators (PI) from Guangdong, followed by Beijing (
interpretationIn the past 16 years, the development of anti-lung cancer drug clinical trials has achieved much progress in mainland China. The most progress lied in targeted therapy and immunotherapy.
fundingThis work was financially supported in part by China National Major Project for New Drug Innovation (2017ZX09304015) and Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (CIFMS) (2016-I2M-1-001).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.